Maintenance and plasticity of striatal neurons is dependant on brain-derived neurotrophic factor (BDNF), which is depleted in the Huntington's disease striatum due to reduced expression and disrupted corticostriatal transportation. In this study we demonstrate that overexpression of BDNF in the striatum attenuates motor impairment and reduces the extent of striatal damage following quinolinic acid lesioning. Transfer of the BDNF gene to striatal neurons using serotype 1/2 adenoassociated viral vectors enhanced BDNF protein levels in the striatum, but induced weight loss and seizure activity following long-term high-level expression. Lower concentration BDNF expression supported striatal neurons against excitotoxic insult, as demonstrated by enhanced krox-24 immunopositive neuron survival, reduction of striatal atrophy and maintenance of the patch/matrix organization. Additionally, BDNF expression attenuated motor impairment in the forelimb use cylinder test, sensorimotor neglect in the corridor food selection task and reversed apomorphine-induced rotational behaviour. Direct correlations were shown for the first time between BDNF-mediated attenuation of behavioural impairment and the integrity of the globus pallidus, seemingly independent from the severity of striatal lesioning. These results demonstrate that BDNF holds considerable therapeutic potential for alleviating both neuropathological and motor function deficits in the Huntington's disease brain, and the critical role of pallidal neurons in facilitating motor performance. Gene Therapy (2008) 15, 966-977;
Introduction
With no efficient treatment currently available in the clinic to alleviate or compensate for neuronal cell loss in Huntington's disease (HD), novel treatment strategies including gene transfer technologies to direct localized production of a biotherapeutic in the striatum are being investigated. While the molecular mechanisms by which an expanded polyglutamine tract leads to the selective loss of striatal neurons in HD patients is still to be fully elucidated, attention has been given to endogenously expressed neurotrophic factors known to play a critical role in the development and maintenance of the nervous system, including brain-derived neurotrophic factor (BDNF), [1] [2] [3] [4] glial-derived neurotrophic factor 1, [5] [6] [7] and ciliary neurotrophic factor [8] [9] [10] [11] [12] to provide a broad approach to attenuate neurodegenerative processes.
A depletion in BDNF within the striatum 13 caused by the disruption of BDNF gene transcription [14] [15] [16] and intracellular transportation of BDNF-containing vesicles by mutant huntingtin protein 17, 18 has been proposed to contribute to the selective vulnerability of striatal projection neurons to neurodegenerative processes in the HD brain. Striatal neurons are dependant on high levels of BDNF for survival, 19 with BDNF being released into the striatum in an activity-dependent manner important for maintaining striatal plasticity. 20, 21 Disruption of wild-type BDNF expression by crossmating bdnf +/À mutants with transgenic R6/1 HD mice results in the advancement of behavioural dysfunction and degeneration of the striatal projection neurons. 22, 23 Environmental enrichment studies with transgenic HD mice show reductions in BDNF expression levels in the hippocampus and striatum can be reversed by enrichment delaying the onset of motor and cognitive deficits. 24, 25 It has also been recently reported that the induction and consolidation of long-term potentiation is defective in HD mice, but that it can be rescued through the application of BDNF restoring normal neuron plasticity. 26 Therefore, direct enhancement of BDNF in the HD striatum may compensate for the reduction in endogenously available BDNF and attenuate the degenerative disease process. An increased release of BDNF following cystamine administration has been found to be neuroprotective for HD mice. 27 However, the need for a continuous supply of BDNF to the vulnerable neurons has led to the investigation of gene transfer strategies to direct localized BDNF production within the striatum with partial protection of striatal neurons previously observed with adenoviral vector 4 and adeno-associated viral (AAV) vector gene delivery. 1 To further investigate the potential therapeutic properties of BDNF to prevent the degeneration of striatal neurons in HD we utilized chimeric AAV 1/2 vectors that have high neuronal transduction efficiency 28 to establish continuous high-level BDNF expression in the striatum. In addition to the attenuation of neuropathological changes we investigated the impact that enhanced striatal BDNF expression had on rodent sensorimotor behaviour, correlating the amelioration of behavioural deficits with the extent of quinolinic acid (QA)-induced lesioning.
Results

AAV 1/2 -mediated enhancement of striatal BDNF expression
To enhance the expression of BDNF protein within the striatum prior to challenging the medium spiny projection neurons with QA-induced excitotoxicity, we injected an AAV 1/2 vector containing haemagglutinin (HA)-tagged BDNF unilaterally into the striatum. Control animals received a unilateral injection of an AAV 1/2 vector containing the reporter protein luciferase. Three weeks post-vector delivery transduced cells were observed in an extensive but often irregularly dispersed distribution throughout the rostral-caudal extent of the striatum (Figures 1a-c) . A population of cells within the globus pallidus and substantia nigra pars compacta ipsilateral to the injected striatum were HA positive indicating anterograde and retrograde transportation of the chimeric AAV 1/2 vectors along efferent and afferent striatal projections (Figures 1e and f) . The ipsilateral substantia nigra pars reticulata also displayed HAimmunostaining, although this was mainly restricted to the striatonigral axonal fibres with very few identifiable HA-positive cell bodies (Figure 1f ). However, 5 weeks after AAV 1/2 -BDNF delivery the rats began to display excessive hyperactivity and aggression in their home cages, and weight loss and seizure activity. To reduce the intensity of transgenic BDNF protein expression, the AAV 1/2 -BDNF vector stock was diluted 10-fold reducing the striatal BDNF levels from 46 ± 7 ng mg À1 of total protein to 4.2±0.7 ng mg
À1
. AAV-luciferase treated rats were observed to express B0.05 ng of BDNF per mg total protein. Ten-fold dilution of the AAV 1/2 -BDNF vector restricted the extent and distribution of cellular transduction with the majority of HA-positive cells located close to the site of injection (Figure 1b) . The number of neurons transduced outside the striatum was also considerably reduced with only a few HA-positive cells visually detected in the substantia nigra and globus pallidus (data not shown). However, to prevent the adverse effects observed using AAV 1/2 -BDNF vector stock, all following assessment of BDNF delivery was performed with the lower-titre AAV-BDNF protocol.
AAV 1/2 -BDNF maintains striatal structure following QA insult
To assess the level of neuroprotective support against QA-induced excitotoxic insult imparted by AAV 1/2 -mediated enhancement of striatal BDNF expression, surviving medium spiny striatal projection neurons were visually identified and stereologically quantified by expression of both DARPP-32 and early growth response protein krox-24 (Erg1), which is highly expressed by striatal neurons following mitogen-activated protein kinase signalling. 29, 30 The distribution of AAV 1/2 transduction and resultant transgene expression was visualized by HA or luciferase immunocytochemical staining on adjacent sections to provide a comparison with the overall maintenance of the striatum (Figure 2 ). While AAV 1/2 -luciferase treated rats generally had a well-defined area of striatal lesioning that was largely (Figures 2f-h ). An inverse correlation was evident between areas of extensive BDNF transgene expression and the maintenance of DARPP-32 or krox-24 immunopositive neurons, suggesting a downregulation of DARPP-32 and krox-24 protein expression in the dispersed regions of intensive BDNF expression but maintained expression in adjacent portions of the striatum (Figures 2f-h ).
Stereological quantification of DARPP-32 and krox-24-positive cells demonstrated that AAV 1/2 -BDNF gene delivery was correlated with increased survival of striatal projection neurons in the QA-lesioned striatum relative to the contralateral hemisphere (krox-24: AAV-BDNF 68 ± 8%, PBS/AAV-luciferase 50 ± 6%, t-test Po0.05, Figure 3a ; DARPP-32: AAV-BDNF 65±8%, PBS/AAV-luciferase 47 ± 4%, t-test P ¼ 0.053, Figure  3b ). We also observed overall atrophy of the striatum and enlargement of the adjacent lateral ventricle following QA injection. However, the 25±3% reduction in cross-sectional striatal area observed in control rats was restricted to only 9±6% by the AAV 1/2 -BDNF gene delivery (t-test Po0.05; Figure 3c ).
Quinolinic acid-induced disruption of striatal organization was visually evident by tyrosine hydroxylase (TH) expression in the QA-lesioned striatum ( Figure 4 ). We observed a clear loss of TH-immunopositive fibres in the striatum of control treated rats proximal to the site of QA injection (Figure 4c) , and significant disruption to the structural arrangement of TH fibres in a larger portion of the striatum where the striatal matrix became condensed into tighter bundles surrounding enlarged striosomelike patches (Figure 4b ). QA-induced disruption of TH-positive fibres was considerably less evident in AAV 1/2 -BDNF treated rats with the injected striatum largely displaying maintenance of the normally dispersed arrangement of the TH-positive fibres within the striatal matrix, and less evident depletion of TH proximal to the site of injection (Figures 4d-f) . Integrated density measurements of TH-positive staining in the striatum did not however reveal any greater depletion of TH expression in controls treated animals compared to AAV 1/2 -BDNF treated rats with both groups showing B20% reduction in TH staining compared to the contralateral hemisphere (data not shown).
Neuronal maintenance of the substantia nigra and globus pallidus, the main striatal projection nuclei, were also assessed. No discernable loss of nigral neurons was observed with either TH or parvalbumin immunocytochemistry following QA-induced striatal lesioning. However, afferent innervations by DARPP-32-positive fibres did appear to be partially depleted in the ipsilateral substantia nigra (Figures 5a and b) . Quantification of DARPP-32 immunostaining density demonstrated the relative loss of striatonigral projections in control rats to be 29 ± 3% compared to the contralateral hemisphere, which was significantly reduced to 10±5% by the prior delivery of AAV 1/2 -BDNF (Figure 5c ). Furthermore, DARPP-32-positive striatonigral fibre innervations directly correlated with the relative maintenance of DARPP-32 immunopositive neurons in the QA-lesioned striatum across all rats (Pearson's r ¼ 0.75, Po0.001).
The degeneration of pallidal neurons following QA lesioning was assessed by parvalbumin and NeuN immunostaining. However, considerable variation in the extent of pallidal cell loss was observed between individual rats, which was independent from the extent of striatal lesioning. AAV-luciferase treated rats displayed extensive pallidal neuron loss (15 ± 8% survival), however parvalbumin-positive neurons in the phosphate-buffered saline (PBS) treated control rats were largely maintained (87 ± 18%; t-test Po0.01). Therefore, although the pallidal neurons appeared to remain largely intact following AAV 1/2 -BDNF treatment (96 ± 10%), BDNF attenuates excitotoxic striatal lesioning AP Kells et al we were unable to conclusively determine if their survival was due to AAV 1/2 -BDNF mediated protection against QA-induced insult.
AAV 1/2 -BDNF reduces QA-induced motor function impairment
To assess the development of functional deficits we analysed the performance of each rat in behavioural tests designed to show hemispherical imbalances in brain function resultant of unilateral QA lesioning in the basal ganglia.
Spontaneous exploratory forelimb use test. Spontaneous motor performance was assessed by observing forelimb use during exploratory rearing behaviour in the cylinder test. 31 Delivery of the AAV vectors or PBS did not induce any significant alterations in baseline forelimb use assessed prior to the QA injection, although AAV 1/2 -BDNF treated rats tended towards preferential use of their contralateral forelimb resulting in a small divergence in forelimb use between the control and AAV 1/2 -BDNF treated rats (unpaired t-test Po0.05; Figure 6a ). Following unilateral QA administration the control rats had an immediate shift towards preferential use of their ipsilateral forelimb for spontaneous exploration. In contrast, preferential forelimb use by AAV 1/2 -BDNF treated rats was not significantly affected by the QA injection ( Figure 6a ). Following QA injection into the striatum of AAV 1/2 -BDNF treated rats, the acquirement of a slight contralateral forelimb use preference was reversed with a small shift towards greater ipsilateral forelimb usage, such that overall the rats remained BDNF attenuates excitotoxic striatal lesioning AP Kells et al largely unbiased in contrast to the significant ipsilateral preference of control rats (two-way analysis of variance (ANOVA) Po0.05; Figure 6a ). Non-lesioned AAV 1/2 -BDNF treated rats displayed a small shift towards contralateral forelimb use that was maintained at a constant level throughout the investigation (Figure 6a ). In addition to the forelimb asymmetry scores, AAV 1/2 -BDNF treated rats were observed to maintain a significantly higher level of exploratory activity following QA administration (data not shown). Overall the delivery of AAV 1/2 -BDNF resulted in a significant amelioration of ipsilateral forelimb use bias induced by a unilateral QA striatal lesion with increased BDNF expression tending to enhance use of the contralateral forelimb.
Corridor task. The impact of AAV 1/2 -BDNF delivery on the development of sensorimotor neglect was investigated by analysing the rats' performance in the corridor task. 32 During baseline assessment the rats displayed a fairly even distribution of sugar pellet retrievals from the left and right sides of the corridor with the selection of the dominant hemisphere for treatment skewing the group data slightly towards a preferential retrieval of pellets from the contralateral side of the corridor. Following QA lesioning, the control rats rapidly acquired a strong ipsilateral retrieval bias that persisted throughout the experimental period (Figure 6b ). In stark contrast, injection of AAV 1/2 -BDNF prevented the development of an ipsilateral retrieval bias post-QA with the retrieval preferences remaining unchanged from baseline and significantly separated from the control group (two-way ANOVA post-QA Po0.01; Figure 6b ). The additional cohort of rats included to assess AAV 1/2 -BDNF treatment in the absence of a QA lesion displayed a small shift towards the retrieval of sugar pellets located on the ipsilateral side of the corridor post-AAV delivery, however this change did not result in a significant ipsilateral retrieval bias (P ¼ 0.3) and remained fairly consistent throughout the full testing period.
Apomorphine-induced rotations. The extent of apomorphine-induced rotational behaviour was undertaken to assess imbalances in the dopamine system following unilateral intrastriatal QA injection and subsequent loss of the dopaminoceptive striatal neurons. Apomorphine acts as a non-specific dopamine receptor agonist stimulating dopaminoceptive neurons and thereby induces rotational motor behaviour, generally towards the lesioned striatum. 33 The prevalence of rotational behaviour varied greatly between individual rats from no rotational behaviour to over 20 rotations per min. Some rats, independent of treatment, displayed contralateral rotational dominance in contrast to the majority of control rats that rotated towards the lesioned hemisphere. Although there were no measurable differences between the treatment groups in terms of total rotations, we did observe an overall trend towards increased rotational behaviour after QA injection (data not shown). The non-lesioned AAV 1/2 -BDNF rats also tended to display increased rotational behaviour in spite of not being lesioned and in contrast to the AAV 1/2 -BDNF treated rats that were QA lesioned. Due to selectively lesioning each rat on its naturally dominant striatal hemisphere, the initial baseline rotational behaviour was generally in a contralateral direction. Apomorphine administration after AAV vector delivery but prior to QA injection resulted in a large distribution in the percentage of ipsilateral rotations, with the majority of AAV 1/2 -BDNF treated rats induced to predominantly rotate towards their treated hemisphere following the increase in striatal BDNF protein expression (Figure 6c) . However, 5 weeks following AAV 1/2 -BDNF delivery the non-lesioned rats had reverted to a contralateral rotational dominance suggesting modifications in the dopamine system following continuous expression of BDNF in the striatum (Figure 6c ). Following the Figure 5 Adeno-associated viral (AAV 1/2 )-brain-derived neurotrophic factor (BDNF) delivery to the striatum prior to quinolinic acid (QA) lesioning maintains striatonigral projections. DARPP-32 expression in the substantia nigra demonstrates a relative loss of striatonigral fibre innervations to the ipsilateral nigra following QA lesioning when compared with the contralateral nigra in (a) control rats. However, DARPP-32 immunopositive striatonigral fibres in the ipsilateral nigra of (b) AAV 1/2 -BDNF treated rats were preserved. Scale bar ¼ 2 mm for whole sections and 200 mm for higher magnification images. (c) Integrated density measurements showed a quantified maintenance of DARPP-32 immunoreactivity in the ipsilateral nigra of AAV 1/2 -BDNF treated rats (n ¼ 9) when compared to combined AAV 1/2 -luciferase (n ¼ 5) and phosphate-buffered saline (PBS, n ¼ 5) control treated rats. Plots represent mean±s.e.m., *Po0.01.
BDNF attenuates excitotoxic striatal lesioning AP Kells et al QA lesion, apomorphine-induced rotational behaviour became more unidirectional in all animals although not always in an ipsilateral direction. While the majority of the control treated rats exhibited persistent ipsilateral rotational behaviour, the AAV 1/2 -BDNF treated rats were more evenly divided between predominantly 
Correlations between neuropathological changes and motor function impairment
To determine whether preservation of motor function was dependant on the maintenance of either striatal or pallidal neuronal populations, we assessed correlations between the observed motor functional impairments following QA lesioning and quantified loss of DARPP-32 immunopositive striatal or parvalbumin containing pallidal neurons for each rat.
Spontaneous exploratory forelimb use test. We observed the proportion of exploratory behaviour undertaken by rats with their ipsilateral forelimb following QA injection significantly correlated with the loss of DARPP-32-positive neurons in the striatum (Pearson's r ¼ À0.49, Po0.05; Figure 7a ). However, with prior delivery of AAV 1/2 -BDNF attenuating development of an ipsilateral forelimb use bias, independent analysis for a linear trend between DARPP-32 maintenance and ipsilateral asymmetry score indicated that the extent of ipsilateral bias in AAV 1/2 -BDNF treated rats was not greatly influenced by the number of striatal neurons lost (linear regression P ¼ 0.09). This was in contrast to the strong linear relationship between the loss of DARPP-32 striatal neurons and ipsilateral forelimb use in the control group (linear regression Po0.001; Figure 7a ). Exploratory ipsilateral forelimb use in AAV 1/2 -BDNF treated rats did however appear to be strongly linked to the ipsilateral:contralateral ratio of parvalbumin-positive neurons in the globus pallidus (linear regression Po0.01) with a 1:1 ratio correlating with a non-biased 52 ± 2% ipsilateral asymmetry score (Figure 7b) . Overall, the maintenance of parvalbumin-positive pallidal neurons did not significantly correlate with the ipsilateral asymmetry score (Pearson's r ¼ À0.39, P ¼ 0.10).
Corridor task. Preferential ipsilateral retrieval of sugar pellets in the corridor task correlated significantly with the anatomical state of the globus pallidus (Pearson's r ¼ À0.68, Po0.01; Figure 7d ) but not the extent of striatal cell loss following QA lesioning (Pearson's r ¼ À0.41, Figure 7 Correlation between neuropathological alteration and behavioural impairment following quinolinic acid (QA) lesioning. Assessment for linear correlations between QA-induced behavioural deficits and quantified cell loss in (a, c, e) the striatum and (b, d, f) the globus pallidus was undertaken using the mean post-QA trial data for individual rats in (a, b) the spontaneous exploratory forelimb use test and (c, d) corridor task, and (e, f) data from each independent apomorphine-induced rotational behaviour trial. Behaviour data were plotted against stereological estimates of relative maintenance of DARPP-32-positive striatal neurons and parvalbumin-positive pallidal neurons. Overall Pearson's correlation coefficients are represented by r values. Solid lines represent significantly non-zero linear correlations (Po0.05) and the dotted lines non-significant linear trends for each treatment group.
BDNF attenuates excitotoxic striatal lesioning AP Kells et al P ¼ 0.08; Figure 7c ). Maintenance of pallidal neurons appeared to contribute towards attenuating development of a contralateral sensorimotor neglect following QA injection. Individual AAV 1/2 -BDNF and control group assessment for linear relationships indicated the correlation between sensorimotor neglect and maintenance of pallidal neurons was stronger in AAV 1/2 -BDNF treated rats (linear regression slope ¼ À63±14, Po0.001) than controls (slope ¼ À19 ± 5, Po0.001; Figure 7d ). While we did not observe an overall significant correlation with striatal neuron survival, the percentage of ipsilateral retrievals made by control rats did display a significant linear relationship with the loss of DARPP-32-positive striatal neurons (linear regression slope ¼ À77±19, Po0.01; Figure 7c ). Figure 7f ). This correlation was very significant for control treated rats (linear regression Po0.001) but not so following AAV 1/2 -BDNF delivery (P ¼ 0.07), although both groups displayed similar trends. The direction of apomorphineinduced rotation also appeared to be strongly dependant on the integrity of the globus pallidus with a loss of pallidal neurons resulting in rotational behaviour towards the lesioned side, while apomorphine induced the rats to rotate away from the lesioned hemisphere when the globus pallidus was fully maintained (Figure 7f ).
Discussion
Ongoing development of gene transfer vectors has led to increased transduction efficiency with the chimeric serotype 1/2 AAV vectors that we utilized in the current study providing a considerable enhancement in neuronal transduction compared to the vectors previously used for BDNF gene delivery to the striatum. 1, 4, 34 Incorporating high-expression regulatory elements we consequently produced large quantities of mature BDNF protein locally within the striatum. However, following continuous high-level expression some of the rats become hyperactive, began to losing weight and developed seizures. Consistent with these adverse effects, BDNF has previously been implicated in seizure severity modulated via BDNF activity in the entorhinal cortex and hippocampus, 35, 36 caused appetite suppression following intraventricular infusion 37 and positively regulates locomotor activity. 38 With the massive escalation in striatal BDNF protein levels following undiluted AAV 1/2 -BDNF delivery, and anterograde/retrograde transportation of the AAV 1/2 -BDNF vector to striatal output nuclei, it is probable that the availability of BDNF in the current study was also enhanced in other regions of the rodent brain including the entorhinal cortex. 39 These deleterious welfare issues, which were circumvented by reduced titre AAV 1/2 -BDNF, demonstrate the vital need for the capability to regulate gene expression following in vivo delivery and for full consideration of the potential impact that transportation of the vectors away from the injection site will cause in non-targeted regions of the central nervous system. However, despite the detrimental effects of high BDNF transgene expression on the rats' physical welfare, immunohistochemical analysis of the AAV 1/2 -BDNF treated striatum suggested some striatal protection against QA-induced lesioning was still provided in the initial high-titre trial (data not shown). The overall maintenance of striatal neurons following reduced-titre AAV 1/2 -BDNF delivery was comparable to our earlier AAV 2 -BDNF investigation, 1 suggesting that the AAV 2 serotype vectors commonly being used in clinical applications may be sufficient as gene transfer vectors for neurotrophic factor gene delivery to the striatum despite the lower transduction efficiency relative to newer generation AAV vectors. As has previously being proposed for glial cell line-derived neurotrophic factor, 7 it is possible that very low levels of neurotrophic factors continuously secreted may have considerable neuroprotective activity without inducing deleterious effects, and explain the lack of increased survival of striatal neurons in the current study compared to the previous AAV 2 -BDNF study. 1 Amelioration of QA-induced sensorimotor impairment by prior delivery of AAV 1/2 -BDNF was observed despite limited attenuation of physical striatal lesioning. Although we determined maintenance of striatal neurons to have been enhanced 36-38% by BDNF, the apparent disruption of DARPP-32 and krox-24 protein expression in AAV 1/2 -BDNF transduced neurons suggests the actual survival of striatal neurons may have been greater than estimated. Krox-24, an early response transcription factor, was used as an alternative marker to provide assessment of neuron fate independent of specific phenotypic markers and did not appear to be disrupted to the same extent as DARPP-32. The functional implications of downregulation of protein expression following gene delivery will need serious consideration given the central role of DARPP-32 in mediating intracellular signalling of both dopamine and glutamate in the dopaminoceptive striatal projection neurons. 40 DARPP-32 is reportedly reduced in pre-symptomatic HD mice implying expression may already be affected in HD. 41 Therefore, in the current study we demonstrate that the maintenance of gross striatal volume and preservation of the striosome/matrical cytoarchitecture by AAV 1/2 -BDNF delivery is potentially of greater importance for functional motor performance than the overall number of surviving striatal neurons. The striatum is topographically arranged with sensory and motor areas of the neocortex projecting to the striatum in a highly organized longitudinal arrangement, 42 such that general maintenance of this arrangement by BDNF may have a greater impact on overall sensorimotor coordination than total neuron number. Enhanced preservation of efferent striatal projections observed in this study, specifically the striatonigral connections, may also have contributed to the preservation of motor coordination in the AAV 1/2 -BNDF treated rats. While nigral neurons appeared to be spared from QA-induced toxicity the pallidal neurons were susceptible to the QA injection, although this was highly variable and showed no correlation to the severity of striatal lesioning.
With no evidential relationship between the striatal and pallidal cell loss we performed individual correlation analysis with each of the behavioural tests to determine whether preservation of motor function was dependant on the maintenance of either striatal or pallidal neuronal populations. Direct correlation of motor function impairment following QA-lesioning with induced neuropathological changes has not previously been investigated. We observed that both the development of spontaneous ipsilateral forelimb use bias and contralateral sensorimotor neglect showed a positive correlation with the severity of striatal lesioning in the PBS/AAV-luciferase control rats as expected. However, with only partial protection of the striatum, the significantly reduced severity of motor function deficits exhibited by the AAV 1/2 -BDNF treated rats did not reflect maintenance of the striatum, but instead displayed a close correlation with the maintenance of pallidal neurons. Direct correlation with globus pallidus maintenance was also observed for sensorimotor neglect, but not spontaneous ipsilateral forelimb use in control rats, possibly indicating the greater executive function required in processing the sensory information and making a lateralized selection in the corridor task. AAV 1/2 -BDNF treated rats that had a loss of pallidal neurons were observed to develop ipsilateral forelimb use bias equivalent to that seen in control rats with similar striatal cell loss, suggesting that the overall AAV 1/2 -BDNF amelioration of motor function impairment was potentially the result of a dynamic interaction between maintenance of striatal cytoarchitecture and basal ganglia output via the globus pallidus. The inducement of rotational behaviour following apomorphine administration also reflected the integrity of the globus pallidus with rats that had no loss of parvalbumin-positive neurons preferentially rotating away from the lesioned striatum, while ipsilateral rotations were generally induced post-QA lesioning when the ipsilateral globus pallidus exhibited neuron loss. The generally inconclusive results of apomorphine-induced behavioural testing were not unexpected following partial lesioning of the striatum and highlight the importance of using reliable spontaneous behaviour tests to assess functional impairments.
Although we were unable to determine whether AAV 1/2 -BDNF delivery provided any direct neuroprotective support to the pallidal neurons in this investigation, the significant correlations demonstrated between the maintenance of striatal neurons and attenuation of motor function deficits were indicative of BDNF-derived trophic support mitigating the extent of disruption to functional behaviour. Given the evidential requirement for pallidal neurons to facilitate normal sensorimotor behaviour, it is probable that efferent striatal projections to the globus pallidus, predominantly arising from the striatal matrix, 43 are better maintained in the AAV 1/2 -BDNF treated rats independent of pallidal neuron survival. Assessment of DARPP-32 staining in the substantia nigra demonstrated BDNF-enhanced maintenance of the striatonigral projections, arising from both matrix and striosome compartments. 43 DARPP-32 staining in the globus pallidus is however less defined, although it would be interesting to investigate BDNFenhanced striatopallidal projection survival using axonal tracers.
Conclusion
Despite BDNF's vital role in maintaining striatal function and the reported disruption of BDNF production/ transportation in the HD brain, to date there has only been limited success in alleviating striatal cell loss through the administration of BDNF. 1, 4 In the current study we further demonstrated partial protection of striatal neurons against excitotoxic insult by prior delivery of an AAV 1/2 -BDNF vector to the striatum. In addition, we investigated for the first time the impact of enhanced striatal BDNF expression on the coordination of sensorimotor function, demonstrating considerable amelioration of QA lesion-induced motor impairments following AAV 1/2 -BDNF delivery. However, while AAV 1/2 -BDNF delivery reduced disruption to the gross striatal organization, when we correlated QA-induced neuropathological changes with the extent of motor impairment we found the attenuation of sensorimotor deficits was directly correlated with the integrity of the globus pallidus to a greater extent than the maintenance of DARPP-32-positive striatal neurons. Ultimately, this investigation demonstrated promising potential for BDNF to alleviate both neuropathological and motor function deficits in the HD brain, and the critical role of pallidal neurons in facilitating motor performance.
Materials and methods
AAV vector production and testing
Chimeric serotype -1 and -2 AAV vectors containing HAtagged BDNF (AAV 1/2 -BDNF) or firefly luciferase (AAV 1/2 -luciferase) cDNA sequences regulated by the hybrid chicken b-actin/cytomegalovirus enhancer promoter and a woodchuck post-transcriptional regulatory element were packaged in HEK293 cells by co-transfection with AAV helper plasmids as previously detailed. 44 AAV expression cassette and helper plasmids were kindly supplied by MJ During and D Young (University of Auckland, New Zealand). Recombinant AAV 1/2 particles were purified by heparin affinity column (Amersham Biosciences, Uppsala, Sweden). Genomic titres were determined by real-time PCR: AAV 1/2 -BDNF 2.0 Â 10 12 , AAV 1/2 -luciferase 4.6 Â 10 12 genomic particles per ml. The additional presence of empty AAV particles following heparin column purification was not assessed. 45 Production of functional BDNF protein following cellular transduction was verified in vitro by the induction of calbindin expression following AAV-BDNF transduction of primary embryonic striatal cultures as previously described. 46 
Surgical procedures
Male Wistar rats (starting weight 200-250 g, 7-9 weeks old; University of Auckland Animal Resources Unit) were used in this study with strict adherence to the NZ Animal Welfare Act (1999) and in accordance with international guidelines for animal welfare. The rats were housed in a temperature-and humidity-controlled environment on a 12 h light/dark regime with water available ad libitum. During periods of behavioural testing the rats were dietary restricted to 85% free-feeding weight. Rats were randomly assigned to receive AAV 1/2 -BDNF+QA (n ¼ 7), 10-fold diluted AAV 1/2 -BDNF+QA (n ¼ 9), 10-fold diluted AAV 1/2 -BDNF BDNF attenuates excitotoxic striatal lesioning AP Kells et al without QA (n ¼ 5), AAV 1/2 -luciferase+QA (n ¼ 5) or PBS+QA (n ¼ 5). Animals were deeply anaesthetized with sodium pentobarbital (60 mg kg À1 intraperitoneal) and positioned in a stereotaxic frame for unilateral intrastriatal injection into their naturally dominant hemisphere (as determined from baseline motor function testing). AAV vectors or PBS (2.0+1.0 ml 20% mannitol per site) were injected at two stereotaxic sites (site 1: anterior-posterior (AP) +1.3, medial-lateral (ML) ± 2.4, dorsal-ventral (DV) À5.0; site 2: AP À0.2, ML ±3.4, DV À5.0) at 150 nl min À1 . Three weeks following AAV vector delivery the rats received a 50 nmol QA (400 nl) injection (AP +0.5, ML ± 2.7, DV À5.0). Eight weeks following QA lesioning the rats were deeply anaesthetized with sodium pentobarbital and perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were removed, post-fixed in 4% paraformaldehyde overnight and cyroprotected in 30% sucrose for coronal sectioning.
Behavioural testing
Functional sensorimotor performance in the spontaneous exploratory forelimb use test, 31 corridor task 32 and apomorphine-induced rotations 33 was assessed 1 week before vector delivery, 1 week after vector delivery and periodically for 7 weeks post-QA injection by an investigator blinded to treatment. Forelimb use in the spontaneous exploratory forelimb use test was assessed as a single asymmetry score representing the overall ipsilateral forepaw use for rearing, initial cylinder wall placement and landing during exploratory rearing over a 5 min trial period in a clear 200 mm diameter cylinder. The corridor task assessed preferential left/right food selection from 'adjacent' containers evenly spaced along a narrow corridor with the first 20 sugar pellet retrievals recorded as ipsilateral or contralateral to the treated striatum as previously described by Dowd et al. 32 The corridor task was run twice on consecutive days and the data from the two trials combined. Apomorphine (1 mg kg À1 injected s.c.; Sigma-Aldrich, Sydney, Australia) was administered to induce rotational behaviour assessed using an automated Rotomax Rotometer (AccuScan Instruments, Columbus, OH, USA) system to record ipsi-and contralateral rotations over a 60 min period. The AAV-luciferase and PBS control groups were combined for analysis where there was no significant difference found between the groups (P40.05).
Quantification of transgenic BDNF protein expression
An additional two cohorts of rats were injected with undiluted AAV 1/2 -BDNF (n ¼ 5) and 10-fold diluted AAV 1/2 -BDNF (n ¼ 5) to quantify transgenic BDNF protein expression by enzyme-linked immunosorbent assay. Three weeks post-vector delivery the rats were euthanized and the striatal hemispheres dissected out and snap frozen in liquid nitrogen. Each striatal hemisphere was homogenized in 600 ml of a 50 mM Tris buffer (pH 6.8) containing 0.5% Tween 20, 0.1% sodium azide, 1.5 g l À1 EDTA, 5 mg l À1 pepstatin A and 10 mg l À1 phenylmethylsulphonyl fluoride. Homogenates were centrifuged at 3000 r.p.m. for 15 min at 4 1C and stored at À80 1C. Quantification of BDNF protein was performed using a Promega BDNF E max ImmunoAssay System (Promega, Madison, WI, USA).
Immunocytochemistry and stereological analysis
Coronal sections were cut from the striatum through to the substantia nigra on a sliding microtome set at 40 mm. Eight sets of sections were collected from each brain (320 mm between consecutive sections). Immunocytochemistry was performed on individual sets of free-floating sections using antibodies against the HAepitope tag (1:1000; Covance, Denver, PA, USA) or luciferase (1:10000; Chemicon, Temecula, CA, USA), DARPP-32 (1:750; Chemicon), krox-24 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), parvalbumin (1:5000; Swant, Bellinzona, Switzerland) and TH (1:500; Chemicon). Biotinylated secondary antibodies (goat antimouse, goat anti-rabbit, rabbit anti-goat; Sigma-Aldrich) were used at 1:500 dilutions followed by incubation with ExtrAvidin peroxidase (1:500; Sigma-Aldrich). Antibodies were visualized using 0.4 mg ml À1 diaminobenzidine, 25 mg ml À1 nickel sulphate, 0.005% hydrogen peroxide in 0.2 M phosphate buffer. Stereological quantification of striatal neurons was performed blind to treatment group using StereoInvestigator (MicroBrightField, Williston, VT, USA) optical fractionator probes over eight coronal sections (equispaced at 320 mm apart) through the contraand ipsilateral striatum spanning the AAV vector and QA injection sites using the lateral ventricle, corpus callosum and internal capsule to define the striatal borders. Staining intensity measurements of the DARPP-32 fibre innervations of the substantia nigra were performed on digital images of three coronal sections (equispaced at 320 mm) through the nigra captured under a Â 4 objective lens. The substantia nigra region was outlined using ImageJ software (National Institutes of Health, USA) and recording integrated area-density measurements of the DARPP-32 staining for both contralateral and ipsilateral hemispheres. All statistical analysis was performed using Prism4 (GraphPad Software, San Diego, CA, USA). The AAV-luciferase and PBS control groups were combined for analysis where there was no significant difference found between the groups (P40.05).
